AMENDMENTS TO THE CLAIMS:

- 1. (Currently Amended) A composition for use in treating epithelial lesions formed of a combination of ingredients comprising:
 - 8-hydroxyquinoline in an amount of at least five percent of the composition by weight;
 - an escharotic chelatable metal agent bonded to said 8-hydroxyquinoline, the escharotic chelatable metal agent comprising a metal having an oxidation state of +2 present in a concentration of at least five percent by weight of the composition and less than an amount that produces an eschar in healthy mammalian tissues; and

a carrier.

- the composition being a pharmaceutical grade material having a capacity for treating at least one type of lesion selected from the group consisting of venereal warts, male veruoca warts, lesions produced by the human papilloma virus, basal cell carcinoma, solar keratosis, Kaposi's sarcoma, eye cancer, sarcoids, sarcoma, malignant melanoma, rectal adenoma, histocytoma, sebaceous adenoma, lung cancer, breast cancer, and colon cancer.
- 2. (Currently Amended) The composition as set forth in claim 1, wherein the 8-hydroxyquinoline and the escharotic chelatable metal agent includes zinc are present in a molar ratio (8-hydroxyquinoline:escharotic chelatable metal-agentzinc) ranging from 1:1 to 1:3-by-weight.
- 3. (Currently Amended) The composition as set forth in claim 2 wherein said molar ratio is about 1:2.
- 4. (Previously Amended) The composition as set forth in claim 1 wherein said escharotic chelatable metal agent comprises zinc.
- 5. (Currently Amended) The composition as set forth in claim 1 wherein said escharotic chelatable metal agent comprises zinc chloride in an amount <u>ranging</u> up to forty percent by weight of said composition by weight.

- 6. (Currently Amended) The composition as set forth in claim 1 wherein said escharotic chelatable metal agent comprises zinc chloride in an amount ranging up to twenty percent of said composition by weight.
- 7. (Previously Amended) The composition as set forth in claim 1 in combination with necrotic tissue from a lesion of said group produced by the action of said composition upon the lesion.

8-13. (Cancelled.)

- 14. (Currently Amended) The composition as set forth in claim 1, wherein said carrier comprises is a gel-base.
- 15. (Currently Amended) The composition as set forth in claim 14 wherein said gel base is comprises a polyoxyalkylene ether derivative of propylene glycol.
- 16. (Original)The composition as set forth in claim 1 wherein said carrier contains a penetrant.
- 17. (Original) The composition as set forth in claim 1 wherein said penetrant is lecithin.
- 18. (Original) The composition as set forth in claim 1 wherein said penetrant is dimethyl sulfoxide.
- 19. (Currently Amended) The composition as set forth in claim 1 wherein said carrier contains means for functioning as an antioxidant.
- 20. (Currently Amended) The composition as set forth in claim 19 wherein said antioxidant includes is selected-from the group consisting of nordihydroguiaretic acid, nordihydroguiaretic acid derivatives, and functional homologues of nordihydroguiaretic acid.
- 21. (Currently Amended The composition as set forth in claim 19 wherein said antioxidant includes is selected from a group consisting of ascorbic acid, ascorbic acid derivatives, and functional homologues of ascorbic acid.

22-33 (Cancelled)

- 34. (Original) The composition as set forth in claim 1 wherein said carrier consists essentially of an antioxidant.
- 35. (Original) The composition as set forth in claim 34 wherein said antioxidant consists essentially of an ascorbate.
- 36. (Original) The composition as set forth in claim 34 wherein the antioxidant consists essentially of nordihydroguiaretic acid.

37-38 (Cancelled)

- 39. (Currently Amended) A composition for use in treating epithelial lesions formed of a combination of ingredients comprising:
 - 8-hydroxyquinoline in an amount of at least five percent of the composition by weight;
 - zinc chloride bended to said 8 hydroxyquinoline, the zinc being present in a concentration of at least five percent by weight of the composition and less than an amount that produces an eschar in healthy mammalian tissues; and

a carrier.

- 40. (Previously Presented) The composition of claim 39, the 8-hydroxyquinoline and the zinc being present in effective amounts for treating at least one type of lesion selected from the group consisting of venereal warts, male veruoca warts, lesions produced by the human papilloma virus, basal cell carcinoma, solar keratosis, Kaposi's sarcoma, eye cancer, sarcoids, sarcoma, malignant melanoma, rectal adenoma, histocytoma, sebaceous adenoma, lung cancer, breast cancer, and colon cancer.
- 41. (Previously Presented) The composition as set forth in claim 39, wherein the 8-hydroxyquinoline and the zinc are present in a ratio (8-hydroxyquinoline:zinc) ranging from 1:1 to 1:3 by weight.

- 42. (Previously Presented) The composition as set forth in claim 41, wherein the ratio is about 1:2.
- 43. (Currently Amended The composition as set forth in claim 41, wherein the 8-hydrozyquinoline 8-hydrozyquinoline is present in an amount ranging up to twenty percent.
- 44. (Previously Presented) The composition as set forth in claim 39 in combination with necrotic tissue from a lesion of said group produced by the action of the composition upon the lesion.
- 45. (Previously Presented) The composition as set forth in claim 39, wherein the carrier is a gel base.
- 46. (Previously Presented) The composition as set forth in claim 45, wherein the gel base is a polyoxyalkylene ether derivative of propylene glycol.
- 47. (Previously Presented)The composition as set forth in claim 39, wherein the carrier contains a penetrant.
- 48. (Previously Presented) The composition as set forth in claim 39, wherein the penetrant is lecithin.
- 49. (Previously Presented) The composition as set forth in claim 39, wherein the penetrant is dimethyl sulfoxide.
- 50. (Previously Presented) The composition as set forth in claim 39, wherein the carrier contains an antioxidant.

51-52 (Cancelled)